Shenqi Fuzheng Injection Combined with Chemotherapy for Breast Cancer: A Meta-Analysis of Randomized Controlled Trials

Purpose.To evaluate the therapeutic effectiveness and safety of shenqi fuzheng injection (SFI) in the associated chemotherapy of breast cancer.Methods. 1247 subjects were included in this study for meta-analysis with RevMan 5.3.Results. The clinical curative effective rate (OR = 2.03, 95% Cl [1.44, 2.86],P<0.0001), grades of KPS (OR = 4.11, 95% Cl [2.74, 6.16],P<0.00001), CD3+cells (MD = 7.05, 95% Cl [0.45, 13.64],P=0.04) and CD4+cells (MD = 8.60, 95% Cl [2.67, 14.54],P=0.004) and CD4/CD8+cells (MD = 0.35, 95% Cl [0.14, 0.56],P=0.001), WBC (OR = 0.30, 95% Cl [0.20, 0.46],P≤0.0001), PLT (OR = 0.36, 95% Cl [0.20, 0.67],P=0.001), gastrointestinal reaction (OR = 0.21, 95% Cl [0.14, 0.32],P<0.00001), and ECG (OR = 0.26, 95% Cl [0.13, 0.51],P<0.0001) in the experimental group were superior to the control group. While there were no differences between two groups in CD8+(MD = 0.21, 95% Cl [−2.81, 3.23],P=0.89), NK+(MD = 1.06, 95% Cl [−9.40, 11.53],P=0.84), RBC (OR = 0.49, 95% Cl [0.14, 1.74],P=0.27), liver function (OR = 0.59, 95% Cl [0.28, 1.24],P=0.16), renal function (OR = 0.56, 95% Cl [0.13, 2.45],P=0.44), and bone marrow suppression (OR = 0.50, 95% Cl [0.25, 1.01],P=0.05).Conclusion. SFI combined with chemotherapy, to some extent, can improve the effectiveness and the security in the treatment of breast cancer; the mechanism may be related to the elevated immunity.

Download Full-text

Shenqi Fuzheng Injection in the Treatment of Breast Cancer: A Meta-analysis of Randomized Controlled Trials

Integrative Cancer Therapies ◽

10.1177/1534735418816824 ◽

2018 ◽

Vol 18 ◽

pp. 153473541881682 ◽

Cited By ~ 5

Author(s):

Shuyu Liu ◽

Dan Zhang ◽

Jiarui Wu ◽

Kaihuan Wang ◽

Yi Zhao ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Controlled Trials ◽

Meta Analysis ◽

Performance Status ◽

Cochrane Collaboration ◽

Effective Rate ◽

Current Evidence ◽

Controlled Trials ◽

Randomized Controlled ◽

Shenqi Fuzheng Injection

Objective: This meta-analysis synthesized the available evidence on the effectiveness and safety of Shenqi Fuzheng injection (SQFZI) combined with chemotherapy for breast cancer. Method: A comprehensive systematic literature search was conducted to identify the randomized controlled trials (RCTs) on breast cancer treated by SQFZI in several electronic database up to October 29, 2017. The included RCTs were assessed using the Cochrane Collaboration tool; data were extracted and analyzed via RevMan 5.3 and Stata 13.0 software. Results: A total of 31 eligible RCTs comprising 2543 participants were selected in this present meta-analysis. The results demonstrated that compared with receiving conventional chemotherapy alone, SQFZI treatment combined with chemotherapy was more efficient in improving clinical total effective rate (relative risk [RR] = 1.31, 95% CI 1.19-1.44, P < .00001) and performance status (RR = 2.23, 95% CI 1.88-2.65, P < .00001). Additionally, SQFZI combined with chemotherapy was capable of enhancing immune function and alleviating adverse drug reactions for patients with breast cancer. Conclusions: The current evidence suggested that using SQFZI as an adjunct treatment to chemotherapy may be preferable for patients with breast cancer compared to chemotherapy alone. Because of the limitations of the quantities and qualities of included RCTs, more well-designed RCTs are needed to further support our conclusion.

Download Full-text

Meta-Analysis of Randomized Controlled Trials of Xueshuantong Injection in Prevention of Deep Venous Thrombosis of Lower Extremity after Orthopedic Surgery

Evidence-based Complementary and Alternative Medicine ◽

10.1155/2020/8877791 ◽

2020 ◽

Vol 2020 ◽

pp. 1-9

Author(s):

Shu-ting Yan ◽

Feng Gao ◽

Tai-wei Dong ◽

Hao Fan ◽

Miao-miao Xi ◽

...

Keyword(s):

Lower Extremity ◽

Venous Thrombosis ◽

Deep Venous Thrombosis ◽

Randomized Controlled Trials ◽

Orthopedic Surgery ◽

Meta Analysis ◽

Control Group ◽

Controlled Trials ◽

Randomized Controlled ◽

Experimental Group

Objective. To systematically evaluate the clinical efficacy of Xueshuantong injection (Panax notoginseng saponins) in preventing deep venous thrombosis (DVT) of lower extremity after orthopedic surgery. Methods. The randomized controlled trials (RCTs) of Xueshuantong injection in prevention of lower extremity DVT after orthopedic surgery were retrieved from CNKI, Wanfang database, VIP, PubMed, and Cochrane Library by August 2020. Revman5.2 was used to analyze the results. Results. A total of 20 articles including 2336 patients were included. The results of meta-analysis showed that the incidence of DVT in the experimental group was lower than that in the control group; after operation, the D-dimer (Ddimer), thrombin time (APTT), and prothrombin time (PT) in the experimental group were significantly improved compared with those in the control group, and the difference between the two groups was statistically significant. Conclusion. Xueshuantong injection can effectively prevent the formation of lower extremity DVT after orthopedic surgery and antagonize the postoperative hypercoagulable state of blood, which has high clinical value.

Download Full-text

A Meta-analysis of Acupuncture Treatment for Irritable Bowel Syndrome

Journal of Integrative Medicine ◽

10.30564/jim.v10i2.3373 ◽

2021 ◽

Vol 10 (2) ◽

Author(s):

Biwei Chen ◽

Lili Zhang ◽

Shaozong Chen ◽

Changzhen Gong

Keyword(s):

Irritable Bowel Syndrome ◽

Clinical Research ◽

Randomized Controlled Trials ◽

Meta Analysis ◽

Cochrane Library ◽

Control Group ◽

Controlled Trials ◽

Randomized Controlled ◽

Irritable Bowel ◽

Experimental Group

To assess the efficacy of acupuncture for treatment of irritable bowel syndrome through meta-analysis of randomized controlled trials in recent 20 years. Online databases, including CNKI, VIP, WANFANG,PubMed, Cochrane Library, Web of Science and Embase were searched for randomized controlled trials (RCTs) of acupuncture for IBS. Retrieval time was from January 1, 2000 to January 31, 2021. According to Jadad scoring criteria,the bias risk and quality assessment of each RCT included were evaluated by two researchers. RevMan 5.3 software was used for the meta analysis. Eight RCTs were selected which include a total of 1181 patients.The control group has 425 patients and the experimental group has 756 patients. The result of meta-analysis indicates that the total effective rate for the experimental group was superior to that of the control group [OR=3.29,95%CI [2.16~5.03](P<0.01)], and the funnel plot was basically symmetric. Acupuncture therapy is shown to have a good safety and compliance record. However, the number of high-quality trials is small, and there are some deficiencies in the methodology of clinical research. Acupuncture, as a supplementary therapy for irritable bowel syndrome, has positive clinical significance and prospects for application. The methodology of clinical research needs to be further improved.

Download Full-text

Efficacy of acupuncture in the management of post-apoplectic aphasia: a systematic review and meta-analysis of randomized controlled trials

BMC Complementary and Alternative Medicine ◽

10.1186/s12906-019-2687-1 ◽

2019 ◽

Vol 19 (1) ◽

Cited By ~ 2

Author(s):

He-yong Tang ◽

Wei Tang ◽

Feng Yang ◽

Wei-wei Wu ◽

Guo-ming Shen

Keyword(s):

Randomized Controlled Trials ◽

Total Effective Rate ◽

Meta Analysis ◽

Effective Rate ◽

Scalp Acupuncture ◽

Control Group ◽

Controlled Trials ◽

Randomized Controlled ◽

Oral Expression ◽

Needle Acupuncture

Abstract Background Aim of this study was to evaluate the effectiveness of scalp, tongue, and Jin’s 3-needle acupuncture for the improvement of postapoplectic aphasia. Method PubMed, Cochrane, Embase databases were searched using index words to identify qualifying randomized controlled trials (RCTs). Meta-analyses of odds ratios (OR) or standardized mean differences (SMD) were performed to evaluate the outcomes between investigational (scalp / tongue / Jin’s 3-needle acupuncture) and control (traditional acupuncture; TA and/or rehabilitation training; RT) groups. Results Thirty-two RCTs (1310 participants in investigational group and 1270 in control group) were included. Compared to TA, (OR 3.05 [95% CI: 1.77, 5.28]; p<0.00001), tongue acupuncture (OR 3.49 [1.99, 6.11]; p<0.00001), and Jin’s 3-needle therapy (OR 2.47 [1.10, 5.53]; p = 0.03) had significantly better total effective rate. Compared to RT, scalp acupuncture (OR 4.24 [95% CI: 1.68, 10.74]; p = 0.002) and scalp acupuncture with tongue acupuncture (OR 7.36 [3.33, 16.23]; p<0.00001) had significantly better total effective rate. In comparison with TA/RT, scalp acupuncture, tongue acupuncture, scalp acupuncture with tongue acupuncture, and Jin’s three-needling significantly improved ABC, oral expression, comprehension, writing and reading scores. Conclusion As treatments to postapoplectic aphasia, scalp / tongue acupuncture and Jin’s Three-needling are found better than TA and/or RT in yielding total effective rate and improving ABC, oral expression, comprehension, reading and writing scores.

Download Full-text

Efficacy of Chinese Herbal Injections for Elderly Patients With pneumonia—A Bayesian Network Meta-analysis of Randomized Control Trials

Frontiers in Pharmacology ◽

10.3389/fphar.2021.610745 ◽

2021 ◽

Vol 12 ◽

Author(s):

Yang Yuan ◽

Quan Zheng ◽

Zhilin Si ◽

Juhua Liu ◽

Zhi Li ◽

...

Keyword(s):

Elderly Patients ◽

Randomized Controlled Trials ◽

Clinical Symptoms ◽

Meta Analysis ◽

Indirect Evidence ◽

Effective Rate ◽

Control Group ◽

Controlled Trials ◽

Randomized Controlled ◽

Chinese Herbal

Background: Pneumonia is a prevalent and complicated disease among adults, elderly people in particular, and the debate on the optimal Chinese herbal injections (CHIs) is ongoing. Our objective is to investigate the comparative effectiveness of various CHIs strategies for elderly patients with pneumonia.Methods: A comprehensive search strategy was executed to identify relevant randomized controlled trials (RCTs) by browsing through several databases from their inception to first, Feb 2020; All of the direct and indirect evidence included was rated by Network meta-analysis under a Bayesian framework.Results: We ultimately identified 34 eligible randomized controlled trials that involved 3,111 elderly participants and investigated 4 CHIs combined with Western medicine (WM) (Xiyanping injection [XYP]+WM, Yanhuning injection [YHN]+WM, Tanreqing injection [TRQ]+WM, Reduning injection [RDN]+WM), contributing 34 direct comparisons between CHIs. Seen from the outcome of Clinical effective rate and time for defervescence, patients taking medicine added with CHIs [Clinical effective rate, XYP + WM(Odd ratio (OR): 0.74, 95%Credible intervals (CrIs):0.55–0.98), YHN + WM(OR: 0.66, 95%CrI: 0.45–0.95), TRQ + WM(OR: 0.65, 95%CrI: 0.50–0.83), RDN + WM(OR: 0.60, 95%CrI: 0.40–0.89); Time for defervescence, YHN + WM(Mean difference (MD): −2.11, 95%CrI: −3.26 to −0.98), XYP + WM(MD: −2.06, 95%CrI: −3.08 to −1.09), RDN + WM(MD: −1.97, 95%CrI: −3.61 to −0.35), TRQ + WM(MD: −1.69, 95%CrI: −2.27 to −1.04)] showed statistically better effect compared with participants in the Control group (CG) who only took WM. Meanwhile, based on the time for disappearance of cough, 3 out of 4 CHIs [TRQ + WM(MD: −2.56, 95%CrI: −3.38 to −1.54), YHN + WM(MD: −2.36, 95%CrI: −3.86 to −1.00) and XYP + WM(MD: −2.21, 95%CrI: −3.72 to −1.10)] strategies indicated improvement of clinical symptoms. Only XYP + WM(MD −1.78, 95%CrI: −3.29 to −0.27) and TRQ + WM (MD: −1.71, 95%CrI: −2.71 to −0.73) could significantly shorten the time for disappearance of pulmonary rales.Conclusion: According to the statistical effect size (The surface under the cumulative ranking), we found that XYP + WM was presumably to be the preferable treatment for treating elderly patients with pneumonia compared with WM alone in terms of clinical effective rate. Our findings were based on very limited evidence and thus should be interpreted with caution. The application of the findings requires further research.

Download Full-text

The Safety and Effectiveness of Bevacizumab in the Treatment of Nonsquamous Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

BioMed Research International ◽

10.1155/2021/5537899 ◽

2021 ◽

Vol 2021 ◽

pp. 1-10

Author(s):

Yue Zhou ◽

Mei He ◽

Rui Li ◽

Yuan Peng ◽

Feng Li ◽

...

Keyword(s):

Adverse Reactions ◽

Meta Analysis ◽

Small Cell ◽

Control Group ◽

Controlled Trials ◽

Small Cell Lung ◽

Randomized Controlled ◽

Significant Difference ◽

Hemorrhagic Events ◽

Experimental Group

Objective. Bevacizumab was currently available for nonsquamous non-small-cell lung cancer (NSqNSCLC) patients and has been studied in several randomized controlled trials (RCTs) for treatment of these patients. This meta-analysis summarizes the most up-to-date evidences regarding the effects and adverse reactions of bevacizumab in the treatment of NSqNSCLC patients. Methods. The authors searched for RCTs from electronic database including PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials. Experimental arm was defined as the bevacizumab-containing group and the control arm as the bevacizumab-free group. Data of objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and adverse reactions were synthetically extracted. A protocol for this meta-analysis has been registered on PROSPERO (http://www.crd.york.ac.uk/prospero). Results. Ten RCTs that involved a total of 3134 patients were included. The experimental group was associated with significant superior ORR (RR 1.63, 95% CI 1.24 to 2.14, P < 0.001 ), OS (HR 0.90, 95% CI 0.82 to 0.99, P < 0.001 ), and prolonged PFS (HR 0.68, 95% CI 0.62 to 0.74, P < 0.001 ) compared to the control. No significant difference was observed regarding DCR (RR 1.13, 95% CI 0.99 to 1.30, P = 0.08 ). The experimental group showed higher rate of hypertension (RR 6.91, 95% CI 4.62 to 10.35, P < 0.00001 ) and hemorrhagic events (RR 3.07, 95% CI 1.78 to 5.30, P < 0.0001 ) than the control group. The experimental group showed lower rate of anemia (RR 0.72, 95% CI 0.55 to 0.96, P = 0.02 ) than the control group. No significant difference was observed regarding treatment-related adverse event grade 3-5 (TRAE3-5) (RR 1.23, 95% CI 0.99 to 1.53, P = 0.06 ), thrombocytopenia (RR 1.11, 95% CI 0.92 to 1.33, P = 0.29 ), and neutropenia (RR 1.11, 95% CI 0.88 to 1.40, P = 0.36 ). Conclusion. This meta-analysis showed that bevacizumab could increase ORR, OS, and prolonged PFS for treatment of NSqNSCLC patients. However, no significant improvement in DCR was observed and bevacizumab could increase the rate of hypertension and hemorrhagic events. Bevacizumab was an acceptable option for NSqNSCLC patients. This trial is registered with PROSPERO registration number: CRD42021226790.

Download Full-text

Efficacy of Liraglutide in Patients With Diabetic Nephropathy: A Meta-Analysis of Randomized Controlled Trials

10.21203/rs.3.rs-929327/v1 ◽

2021 ◽

Author(s):

Niroj Mali ◽

Feng Su ◽

Jie Ge ◽

WenXing Fan ◽

Jing Zhang ◽

...

Keyword(s):

Diabetic Nephropathy ◽

Blood Glucose ◽

Randomized Controlled Trials ◽

Meta Analysis ◽

Renal Outcome ◽

Cochrane Library ◽

Control Group ◽

Controlled Trials ◽

Randomized Controlled ◽

Experimental Group

Abstract Background: The efficacy of liraglutide to treat type 2 diabetic nephropathy (T2DN) remains controversial. Thus, we conducted this meta-analysis to systematically evaluate the clinical effect of liraglutide on T2DN patients. Methods: Eight databases (PubMed, Web of Science, the Cochrane Library, EMBASE, Chinese National Knowledge Infrastructure (CNKI), Wanfang database, China Science and Technology Journal Database and China Biology Medicine Database (CBM)) were searched for published articles to evaluate the clinical efficacy of liraglutide in subjects with T2DN. The Revman 5.3 and Stata 13 softwares were used for analyses and plotting. Results: A total of 18 randomized controlled trials (RCTs) with 1580 diabetic nephropathy patients were screened. We found that the levels of UACR, Scr, Cysc were lower in experimental group of T2DN patients treated with liraglutide than control group intervened without liraglutide. Liraglutide also reduced the levels of blood glucose (including FBG, PBG and HbA1c), body mass index (BMI), and anti-inflammatory indicators (TNF–α, IL-6). However, there was no significant difference in BUN and eGFR between experimental group and control group.Conclusions: Liraglutide reduced the levels of Blood Glucose, BMI, renal outcome indicators and serum inflammatory factors of patients with T2DN, suggesting the beneficial effects of liraglutide on renal function.

Download Full-text